Core Insights - Nutriband Inc. provided an update on key milestones and discussions from the Annual Shareholders Meeting held on January 24, 2026, in Orlando, Florida [1] Group 1: Leadership Changes - Two new directors were added to the board: Alessandro Puddu, an Italian Chartered Accountant with over 10 years of experience in audit and corporate advisory [2][3][5], and Viorica Carlig, a senior executive with over a decade of leadership experience in service-based companies and a Ph.D. in Economics [6] Group 2: Product Development - Nutriband is focusing on the development of its AVERSA™ FENTANYL product, with significant milestones including a strengthened collaboration with Kindeva for product development and a granted patent in Macao [9] - The company completed the commercial manufacturing process scale-up for AVERSA™ FENTANYL and issued a new US patent expanding its intellectual property protection [9] - A Type C meeting was held with the US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL [9] - Nutriband filed a new provisional patent application covering improved aversive formulations and initiated the development of a worldwide commercial brand name for AVERSA™ FENTANYL [9] Group 3: Financial Updates - The company is in the process of finalizing the sale of its Pocono subsidiary, with a nonrefundable penalty of $10,000 per week collected, totaling $30,000 so far [10] - A complaint was filed with FINRA regarding suspected naked short selling on behalf of shareholders [11] - The company reminded shareholders that warrants issued during its NASDAQ uplisting will expire on October 1, 2026, with 91,090 warrants set to expire at a strike price of $6.43, totaling $5,856,112 if exercised [12] Group 4: Technology Overview - Nutriband's AVERSA™ technology incorporates aversive agents into transdermal patches to prevent drug abuse and misuse, with a broad intellectual property portfolio covering multiple countries [13][14]
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points